Introduction
Abiraterone, sold under the trade name Zytiga, is an androgen biosynthesis inhibitor used to treat advanced prostate cancer. It works by reducing the production of androgens (male hormones) not only in the testes but also in the adrenal glands and prostate tumor tissue, providing comprehensive hormonal control.
Purpose
- Treats metastatic castration-resistant prostate cancer (mCRPC).
- Treats metastatic castration-sensitive prostate cancer (mCSPC) in combination with prednisone and androgen deprivation therapy (ADT).
- Delays disease progression and improves survival in advanced prostate cancer.
How It Works
Abiraterone inhibits the enzyme CYP17, which is critical for androgen production. This reduces the overall levels of testosterone and other androgens, depriving prostate cancer cells of the hormones they need to grow and spread.
Usage
- Taken as an oral tablet, typically once daily, on an empty stomach.
- Always used in combination with low-dose prednisone to manage side effects related to mineralocorticoid excess (e.g., hypertension, fluid retention).
- Regular monitoring of liver function, potassium levels, and blood pressure is recommended.
Considerations
- Common side effects include fatigue, joint swelling, hot flashes, and elevated liver enzymes.
- Rare but serious side effects include adrenal insufficiency, cardiovascular complications, and severe liver toxicity; patients should be monitored closely.
- Prednisone is necessary to mitigate side effects and balance hormone levels.
At Crossroads Urology
At Crossroads Urology, Abiraterone is a cornerstone of advanced prostate cancer treatment. Our providers work closely with patients to manage therapy and monitor for potential side effects, ensuring safe and effective care.
Conclusion
Abiraterone [Zytiga] offers powerful hormonal control for advanced prostate cancer, improving survival rates and quality of life. Contact Crossroads Urology today to learn more about this treatment and how it can benefit you.